Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR

Nature Reviews Molecular Cell Biology

Volumn 13, Issue 4, 2012, Pages 213-224

  Calkin, Anna C ^a   Tontonoz, Peter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; BILE ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; FATTY ACID SYNTHASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLUCURONOSYLTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN RECEPTOR SUBSTRATE 1; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; OXYSTEROL; PHOSPHOLIPID TRANSFER PROTEIN; RETINOID X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 1; VASCULOTROPIN A; VERY LOW DENSITY LIPOPROTEIN; VITAMIN D RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BROWN ADIPOSE TISSUE; CELL MEMBRANE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; ENERGY EXPENDITURE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEEDBACK SYSTEM; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; LIPID METABOLISM; LIPOGENESIS; LIVER METABOLISM; LIVER TOXICITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE;

ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; LIPID METABOLISM; OBESITY; ORPHAN NUCLEAR RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA-BINDING PROTEINS; STEROLS; TRANSCRIPTION, GENETIC;

EID: 84858796689     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm3312     Document Type: Review

References (119)

1. Glass, C. K. & Rosenfeld, M. G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121-141 (2000). (Pubitemid 30070977)
2. Keller, H. et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl Acad. Sci. USA 90, 2160-2164 (1993). (Pubitemid 23078585)
3. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. & Mangelsdorf, D. J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 383, 728-731 (1996). (Pubitemid 26360651)
4. Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368 (1999). (Pubitemid 29289664)
5. Zelcer, N. & Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signalling. J. Clin. Invest. 116, 607-614 (2006). (Pubitemid 43326865)
6. Hong, C. & Tontonoz, P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18, 461-467 (2008). (Pubitemid 50280209)
7. Apfel, R. et al. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 14, 7025-7035 (1994).
8. Willy, P. J. et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9, 1033-1045 (1995).
9. Repa, J. J. & Mangelsdorf, D. J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16, 459-481 (2000). (Pubitemid 32037514)
10. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med. 9, 213-219 (2003). (Pubitemid 36227724)
11. Rust, S. et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet. 22, 352-355 (1999). (Pubitemid 29369525)
12. Bodzioch, M. et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. 22, 347-351 (1999). (Pubitemid 29369524)
13. Brooks-Wilson, A. et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet. 22, 336-345 (1999). (Pubitemid 29369523)
14. Venkateswaran, A. et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proc. Natl Acad. Sci. USA 97, 12097-12102 (2000).
15. Repa, J. J. et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524-1529 (2000).
16. Kennedy, M. A. et al. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276, 39438-39447 (2001). (Pubitemid 37371322)
17. Tarling, E. J. & Edwards, P. A. ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter. Proc. Natl Acad. Sci. USA 108, 19719-19724 (2011).
18. Wang, N., Lan, D., Chen, W., Matsuura, F. & Tall, A. R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl Acad. Sci. USA 101, 9774-9779 (2004). (Pubitemid 38869312)
19. Kennedy, M. A. et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1, 121-131 (2005). (Pubitemid 43977167)
20. Hong, C. et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. J. Lipid Res. 52, 531-539 (2011).
21. Mak, P. A. et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors-α and-β. J. Biol. Chem. 277, 31900-31908 (2002). (Pubitemid 34968998)
22. Laffitte, B. A. et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA 98, 507-512 (2001). (Pubitemid 32105072)
23. Ken-Dror, G., Talmud, P. J., Humphries, S. E. & Drenos, F. APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men. Mol. Med. 16, 389-399 (2010).
24. Plump, A. S. et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353 (1992).
25. Laffitte, B. A. et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 23, 2182-2191 (2003). (Pubitemid 36278826)
26. Luo, Y. & Tall, A. R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105, 513-520 (2000). (Pubitemid 30127252)
27. Zhang, Y., Repa, J. J., Gauthier, K. & Mangelsdorf, D. J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ. J. Biol. Chem. 276, 43018-43024 (2001).
28. Peet, D. J. et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93, 693-704 (1998). (Pubitemid 28257577)
29. Repa, J. J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14, 2819-2830 (2000).
30. Schultz, J. R. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831-2838 (2000).
31. Repa, J. J. et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors-α and-β. J. Biol. Chem. 277, 18793-18800 (2002). (Pubitemid 34952438)
32. Berge, K. E. et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290, 1771-1775 (2000). (Pubitemid 32004809)
33. Yasuda, T. et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 30, 781-786 (2010).
34. van der Velde, A. E. et al. Direct intestinal cholesterol secretion contributes significantly to total faecal neutral sterol excretion in mice. Gastroenterology 133, 967-975 (2007).
35. van der Veen, J. N. et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284, 19211-19219 (2009).
36. Duval, C. et al. Niemann-Pick C1 like 1 gene expression is downregulated by LXR activators in the intestine. Biochem. Biophys. Res. Commun. 340, 1259-1263 (2006). (Pubitemid 43083413)
37. Zelcer, N., Hong, C., Boyadjian, R. & Tontonoz, P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325, 100-104 (2009).
38. Zhang, L. et al. The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes Dev. 25, 1262-1274 (2011).
39. Calkin, A. C. et al. FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proc. Natl Acad. Sci. USA 108, 20107-20112 (2011).
40. Hong, C. et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J. Biol. Chem. 285, 19720-19726 (2010).
41. Tobin, K. A. et al. Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J. Biol. Chem. 277, 10691-10697 (2002). (Pubitemid 34975649)
42. Chen, G., Liang, G., Ou, J., Goldstein, J. L. & Brown, M. S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl Acad. Sci. USA 101, 11245-11250 (2004). (Pubitemid 39038332)
43. Mitro, N. et al. The nuclear receptor LXR is a glucose sensor. Nature 445, 219-223 (2007). (Pubitemid 46095727)
44. Kalaany, N. Y. et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab. 1, 231-244 (2005). (Pubitemid 43960607)
45. Hummasti, S. et al. Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. J. Lipid Res. 45, 616-625 (2004). (Pubitemid 38405667)
46. Gerin, I. et al. LXRβ is required for adipocyte growth, glucose homeostasis, and β-cell function. J. Biol. Chem. 280, 23024-23031 (2005). (Pubitemid 40861694)
47. Stulnig, T. M. et al. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol. Pharmacol. 62, 1299-1305 (2002). (Pubitemid 35407455)
48. Fernandez-Veledo, S., Nieto-Vazquez, I., Rondinone, C. M. & Lorenzo, M. Liver X receptor agonists ameliorate TNFα-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49, 3038-3048 (2006). (Pubitemid 44730308)
49. Dalen, K. T., Ulven, S. M., Bamberg, K., Gustafsson, J. A. & Nebb, H. I. Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor-α. J. Biol. Chem. 278, 48283-48291 (2003). (Pubitemid 37526713)
50. Ross, S. E. et al. Microarray analyses during adipogenesis: understanding the effects of Wnt signalling on adipogenesis and the roles of liver X receptor-α in adipocyte metabolism. Mol. Cell. Biol. 22, 5989-5999 (2002). (Pubitemid 34815845)
51. Korach-Andre, M., Archer, A., Barros, R. P., Parini, P. & Gustafsson, J. A. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proc. Natl Acad. Sci. USA 108, 403-408 (2011).
52. Laffitte, B. A. et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl Acad. Sci. USA 100, 5419-5424 (2003). (Pubitemid 36542720)
53. Stenson, B. M. et al. Activation of liver X receptor regulates substrate oxidation in white adipocytes. Endocrinology 150, 4104-4113 (2009).
54. Korach-Andre, M. et al. Liver X receptors regulate de novo lipogenesis in a tissue-specific manner in C57BL/6 female mice. Am. J. Physiol. Endocrinol. Metab. 301, E210-E222 (2011).
55. Ogihara, T. et al. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling. J. Biol. Chem. 285, 5392-5404 (2010).
56. Efanov, A. M., Sewing, S., Bokvist, K. & Gromada, J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic β-cells. Diabetes 53 (Suppl. 3), 75-78 (2004).
57. Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693 (1995).
58. Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362-1365 (1999). (Pubitemid 29289663)
59. Song, C. S. et al. Dehydroepiandrosterone sulphotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 276, 42549-42556 (2001).
60. Pircher, P. C. et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278, 27703-27711 (2003). (Pubitemid 36899959)
61. Goodwin, B. et al. A regulatory cascade of the nuclear receptors, FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517-526 (2000).
62. Lu, T. T. et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507-515 (2000).
63. Huber, R. M. et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290, 35-43 (2002). (Pubitemid 34615907)
64. Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744 (2000).
65. Zhang, M. & Chiang, J. Y. Transcriptional regulation of the human sterol 12α-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4α in mediating bile acid repression. J. Biol. Chem. 276, 41690-41699 (2001).
66. Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591 (2003). (Pubitemid 36828786)
67. Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225 (2005).
68. Strautnieks, S. S. et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nature Genet. 20, 233-238 (1998). (Pubitemid 28507666)
69. de Vree, J. M. et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl Acad. Sci. USA 95, 282-287 (1998). (Pubitemid 28103945)
70. Moschetta, A., Bookout, A. L. & Mangelsdorf, D. J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nature Med. 10, 1352-1358 (2004). (Pubitemid 40022717)
71. Chen, F. et al. Liver receptor homologue-1 mediates species-and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278, 19909-19916 (2003). (Pubitemid 36799181)
72. Grober, J. et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 274, 29749-29754 (1999). (Pubitemid 129637899)
73. Landrier, J. F., Eloranta, J. J., Vavricka, S. R. & Kullak-Ublick, G. A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and-β genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G476-G485 (2006).
74. Gnerre, C., Blattler, S., Kaufmann, M. R., Looser, R. & Meyer, U. A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14, 635-645 (2004). (Pubitemid 39411263)
75. Lee, F. Y. et al. Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. Mol. Endocrinol. 24, 1626-1636 (2010).
76. Lambert, G. et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563-2570 (2003). (Pubitemid 36801334)
77. Kast, H. R. et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15, 1720-1728 (2001). (Pubitemid 32939302)
78. Claudel, T. et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125, 544-555 (2003). (Pubitemid 36929436)
79. Sirvent, A. et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 566, 173-177 (2004). (Pubitemid 38625954)
80. Mak, P. A., Kast-Woelbern, H. R., Anisfeld, A. M. & Edwards, P. A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43, 2037-2041 (2002). (Pubitemid 35471069)
81. Watanabe, M. et al. Bile acids lower triglyceride levels via a pathway involving, FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408-1418 (2004). (Pubitemid 39071696)
82. Matsukuma, K. E. et al. Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase. J. Lipid Res. 47, 2754-2761 (2006). (Pubitemid 44936088)
83. Pineda Torra, I. et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor-γ gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17, 259-272 (2003).
84. Zhang, Y., Castellani, L. W., Sinal, C. J., Gonzalez, F. J. & Edwards, P. A. Peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 18, 157-169 (2004). (Pubitemid 38141784)
85. Duran-Sandoval, D. et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280, 29971-29979 (2005). (Pubitemid 41177076)
86. Zhang, Y. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103, 1006-1011 (2006). (Pubitemid 43212212)
87. Ma, K., Saha, P. K., Chan, L. & Moore, D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116, 1102-1109 (2006).
88. Ge, X. et al. Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis. J. Lipid Res. 52, 1561-1568 (2011).
89. Potthoff, M. J. et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 13, 729-738 (2011).
90. Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624 (2011).
91. Ketterer, C. et al. Genetic variation within the NR1H2 gene encoding liver X receptor-β associates with insulin secretion in subjects at increased risk for type 2 diabetes. J. Mol. Med. (Berl.) 89, 75-81 (2011).
92. Dahlman, I. et al. Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet. Genomics 16, 881-889 (2006). (Pubitemid 44772806)
93. Solaas, K. et al. Suggestive evidence of associations between liver X receptor-β polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe). BMC Med. Genet. 11, 144 (2010).
94. Auboeuf, D. et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319-1327 (1997). (Pubitemid 27315281)
95. Grefhorst, A. et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am. J. Physiol. Endocrinol. Metab. 289, E829-E838 (2005). (Pubitemid 41504383)
96. Commerford, S. R. et al. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol. Endocrinol. 21, 3002-3012 (2007). (Pubitemid 350223510)
97. Fernandez-Veledo, S., Vila-Bedmar, R., Nieto-Vazquez, I. & Lorenzo, M. c-Jun N-terminal kinase 1/2 activation by tumour necrosis factor-α induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J. Clin. Endocrinol. Metab. 94, 3583-3593 (2009).
98. Shang, Q., Saumoy, M., Holst, J. J., Salen, G. & Xu, G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G419-G424 (2010).
99. Li, T. et al. Transgenic expression of cholesterol 7α-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52, 678-690 (2010).
100. Bays, H. E., Goldberg, R. B., Truitt, K. E. & Jones, M. R. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168, 1975-1983 (2008).
101. Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51, 771-784 (2010).
102. Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039-11049 (2006). (Pubitemid 43855527)
103. Watanabe, M. et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286, 26913-26920 (2011).
104. Prawitt, J. et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60, 1861-1871 (2011).
105. Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604-7609 (2002). (Pubitemid 34568738)
106. Levin, N. et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25, 135-142 (2005). (Pubitemid 40054266)
107. Verschuren, L., de Vries-van der Weij, J., Zadelaar, S., Kleemann, R. & Kooistra, T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J. Lipid Res. 50, 301-311 (2009).
108. Terasaka, N. et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536, 6-11 (2003). (Pubitemid 36206397)
109. Schuster, G. U. et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 106, 1147-1153 (2002). (Pubitemid 34970858)
110. Bradley, M. N. et al. Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. J. Clin. Invest. 117, 2337-2346 (2007). (Pubitemid 47219578)
111. Tangirala, R. K. et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 99, 11896-11901 (2002). (Pubitemid 34994495)
112. Teupser, D. et al. Effect of macrophage overexpression of murine liver X receptor-α (LXR-α) on atherosclerosis in LDL-receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. 28, 2009-2015 (2008).
113. Bischoff, E. D. et al. Non-redundant roles for LXRα and LXRβ in atherosclerosis susceptibility in low density receptor knockout mice. J. Lipid Res. 51, 900-906 (2010).
114. Zhang, Y. et al. FXR deficiency causes reduced atherosclerosis in Ldlr-/-mice. Arterioscler. Thromb. Vasc. Biol. 26, 2316-2321 (2006). (Pubitemid 44465728)
115. Hanniman, E. A., Lambert, G., McCarthy, T. C. & Sinal, C. J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46, 2595-2604 (2005). (Pubitemid 43107471)
116. Guo, G. L. et al. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 1761, 1401-1409 (2006). (Pubitemid 44822668)
117. Flatt, B. et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 52, 904-907 (2009).
118. Hartman, H. B. et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/-and apoE-/-mice. J. Lipid Res. 50, 1090-1100 (2009).
119. Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296, H272-H281 (2009).